SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485
Debt
Debt-to-Equity Ratio0.30
Current Ratio5.93
Quick Ratio5.93
Price-To-Earnings
Trailing P/E Ratio-1.76
Forward P/E Ratio-2.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales318.87
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book2.39
Profitability
EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-9,450.00%
Return on Equity-78.78%
Return on Assets-43.38%
Miscellaneous
Employees19
Outstanding Shares46,840,000
SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS Inc (NASDAQ:SCYX) issued its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.06. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.10 million. SCYNEXIS had a negative net margin of 9,450.00% and a negative return on equity of 78.78%. View SCYNEXIS's Earnings History.
What price target have analysts set for SCYX?
5 brokers have issued 12 month price targets for SCYNEXIS's stock. Their predictions range from $4.00 to $9.00. On average, they expect SCYNEXIS's share price to reach $6.00 in the next twelve months. View Analyst Ratings for SCYNEXIS.
Are investors shorting SCYNEXIS?
SCYNEXIS saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,580,800 shares, an increase of 103.5% from the May 15th total of 776,675 shares. Based on an average daily trading volume, of 1,030,039 shares, the days-to-cover ratio is presently 1.5 days. Currently, 3.5% of the shares of the company are sold short.
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Catalyst Pharmaceuticals (CPRX), Evelo Biosciences (EVLO), ProMetic Life Sciences (PFSCF), Aquinox Pharmaceuticals (AQXP), DURECT (DRRX), Arbutus Biopharma (ABUS), MediciNova (MNOV), Paratek Pharmaceuticals (PRTK), Corbus Pharmaceuticals (CRBP), Innate Pharma (IPHYF), Seres Therapeutics (MCRB), Minerva Neurosciences (NERV), Clearside Biomedical (CLSD), Corium International (CORI) and Sienna Biopharmaceuticals (SNNA).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Dr. Marco Taglietti, Chief Exec. Officer, Pres and Director (Age 58)
- Mr. Eric Francois, Chief Financial Officer (Age 43)
- Mr. David Gonzalez Angulo M.D., Chief Medical Officer (Age 53)
- Mr. Scott Sukenick J.D., Gen. Counsel
- Dr. Rajeshwar Motheram Ph.D., VP of Pharmaceutical Devel.
Has SCYNEXIS been receiving favorable news coverage?
Media stories about SCYX stock have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. SCYNEXIS earned a media sentiment score of 0.15 on Accern's scale. They also assigned media headlines about the company an impact score of 46.16 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are SCYNEXIS's major shareholders?
SCYNEXIS's stock is owned by many different of institutional and retail investors. Top institutional investors include Federated Investors Inc. PA (14.66%), Caxton Corp (4.09%), DAFNA Capital Management LLC (3.49%), CVI Holdings LLC (2.78%), Rock Springs Capital Management LP (1.75%) and Iguana Healthcare Management LLC (0.85%). Company insiders that own SCYNEXIS stock include David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti, Patrick Machado and Scott Sukenick. View Institutional Ownership Trends for SCYNEXIS.
Which institutional investors are buying SCYNEXIS stock?
SCYX stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Caxton Corp, CVI Holdings LLC, DAFNA Capital Management LLC, Iguana Healthcare Management LLC and Rock Springs Capital Management LP. Company insiders that have bought SCYNEXIS stock in the last two years include David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti, Patrick Machado and Scott Sukenick. View Insider Buying and Selling for SCYNEXIS.
How do I buy shares of SCYNEXIS?
Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYX stock can currently be purchased for approximately $1.79.
How big of a company is SCYNEXIS?
SCYNEXIS has a market capitalization of $92.28 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. SCYNEXIS employs 19 workers across the globe.
How can I contact SCYNEXIS?
SCYNEXIS's mailing address is 101 HUDSON STREET SUITE 3610, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]
MarketBeat Community Rating for SCYNEXIS (SCYX)
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
